It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Radiation-induced gastrointestinal syndrome is a major complication and limiting factor for radiotherapy. Tumor suppressor p53 has a protective role in radiation-induced gastrointestinal toxicity. However, its underlying mechanism remains unclear. Here we report that regulating the IL12-p40/MHC class II signaling pathway is a critical mechanism by which p53 protects against radiation-induced gastrointestinal syndrome. p53 inhibits the expression of inflammatory cytokine IL12-p40, which in turn suppresses the expression of MHC class II on intestinal epithelial cells to suppress T cell activation and inflammation post-irradiation that causes intestinal stem cell damage. Anti-IL12-p40 neutralizing antibody inhibits inflammation and rescues the defects in intestinal epithelial regeneration post-irradiation in p53-deficient mice and prolongs mouse survival. These results uncover that the IL12-p40/MHC class II signaling mediates the essential role of p53 in ensuring intestinal stem cell function and proper immune reaction in response to radiation to protect mucosal epithelium, and suggest a potential therapeutic strategy to protect against radiation-induced gastrointestinal syndrome.
Radiation induced gastrointestinal syndrome is a complication of radiotherapy and the tumor suppressor p53 is implicated in protection from gastrointestinal toxicity. Here Wang and colleagues show that p53 protection against radiation-induced gastrointestinal syndrome involves intestinal stem cell function and inhibition of inflammation triggered by radiation via the IL12- p40/MHC-II axis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Rutgers University, Rutgers Cancer Institute of New Jersey, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796)
2 Hunter College, City University of New York, Department of Biological Sciences, New York, USA (GRID:grid.257167.0) (ISNI:0000 0001 2183 6649)
3 Rutgers University, Rutgers Cancer Institute of New Jersey, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796); Rutgers University, Department of Biological Sciences, Newark, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796); Penn Medicine Princeton Medical Center, Department of Pathology, Plainsboro, USA (GRID:grid.412701.1) (ISNI:0000 0004 0454 0768)
4 Rutgers University, Rutgers Cancer Institute of New Jersey, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796); Rutgers University, Department of Cell Biology and Neuroscience, Piscataway, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796)